View
Multiple Myeloma
Clinical Insights into Managing Myeloma
1. Managing Myeloma: Where We Are, Where We’re Going, and Where We SHOULD Be Going (Time to Choose Sides!)
Speaker details: Dr. Hearn Jay Cho, Dr. Paul G Richardson, Dr. Keith Steward, Dr. Suzanne Lentzsch
The GRIFFIN trial showed that the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) for the treatment of patients with transplant-eligible newly diagnosed multiple myeloma (NDMM) improved response rate and depth of response. 14
Next-gen small molecules and targeted therapies with venetoclax, selinexor, melflufen, etc. also show great promise. Further refinement of prognostics, immune profiling, and minimal residual disease (MRD) will guide therapy. 15
Successful maintenance therapies must be convenient, safe, and welltolerated and should not reduce the use or efficacy of other future treatments. All patients with high-risk multiple myeloma (MM) should receive maintenance therapy. 16
2. Immunotherapy in Multiple Myeloma: Sequencing MM Therapies With and After Antibody Therapies 17
Speaker details: Dr. Niels W.C.J. Van De Donk
The optimal sequence and choice of drugs for MM is not established; however, a better understanding of sequencing therapies can lead to better clinical outcomes.
While lenalidomide has been used in part as firstline therapy, transplantineligible patients benefit from CD 38 antibody in first-line regimens.
The increased use of lenalidomide and CD 38 antibodies as part of the firstline regimens has a major impact on the of the first relapse.
For personalized therapy, the patient’s wishes, comorbidities, toxicity profile, and tumor-related factors should be kept in mind.
The efficacy of retreatment with CD38 antibodies and B cell maturation antigentargeting agents should be further studied.
